Eagle Pharmaceut Stock Price, News & Analysis

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) has announced a settlement agreement with Dr. Reddy’s Laboratories regarding patent litigation related to its drug BENDEKA^®. Under the terms of the settlement, Dr. Reddy’s can market its product starting November 17, 2027, with potential for earlier market entry under specific conditions. This agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. This follows previous settlements with Hospira and Accord Healthcare regarding similar patent claims.

Eagle Pharmaceuticals reported Q4 2022 net income of $8.2 million, or $0.63 per share, compared to a loss of $6.2 million in Q4 2021. Total revenue for Q4 2022 was $60.7 million, an increase from $42.3 million year-over-year. For FY 2022, Eagle achieved net income of $35.6 million, up from a loss of $8.6 million in 2021, with total revenue rising to $316.6 million from $171.5 million. PEMFEXY® achieved $12.1 million in sales in Q4 2022, capturing a 6% market share. The FDA approved PEMFEXY for an additional indication, and the company plans to increase its share to 12% by Q1 2023. Eagle had $55.3 million in cash as of December 31, 2022.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced that CEO Scott Tarriff and CFO Brian Cahill will participate in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2023, at 2:35 PM ET. This event will take place in Miami, FL, and will be available via webcast. Eagle Pharmaceuticals is committed to innovation in medicines that enhance patients' lives, with a diverse product portfolio and a strong pipeline targeting critical areas in oncology and metabolic care.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) will release its fourth quarter and full year 2022 financial results on March 13, 2023, before the market opens. CEO Scott Tarriff and CFO Brian Cahill will host a conference call at 8:30 a.m. ET to discuss the results. Investors can access the call toll-free at 800-445-7795 (U.S.) or 785-424-1789 (International). A replay will be available for two weeks, and the webcast will be archived for 30 days on the company's website.

Eagle specializes in developing innovative medicines and has a portfolio of commercialized products including vasopressin and BENDEKA®. The company focuses on addressing critical care and oncology needs.

Eagle Pharmaceuticals, Inc. (EGRX) reported a net income of $21.3 million for the year ending September 30, 2022, translating to $1.63 per diluted share. The company's adjusted EBITDA stood at $125.6 million, showing substantial growth from 2021. Eagle aims to double its share of the pemetrexed market with projected quarterly revenues of $8 million. The company anticipates an adjusted EBITDA of $74.0-$80.0 million and adjusted non-GAAP earnings per share of $4.20-$4.53 for 2023. Key product growth is expected, especially in PEMFEXY sales, post royalty adjustments.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced that CEO Scott Tarriff and CFO Brian Cahill will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 10:30 AM PT/1:30 PM ET. The presentation will be available as a webcast for 30 days on the company’s website, allowing investors to access key insights into Eagle’s corporate strategies and product pipeline. The company is recognized for its innovative pharmaceutical solutions aimed at improving patient outcomes, with commercialized products across critical care and oncology.

Eagle Pharmaceuticals (Nasdaq: EGRX) announced FDA approval for an additional indication of PEMFEXY (pemetrexed injection) for treating patients with metastatic, non-squamous, non-small cell lung cancer without EGFR or ALK aberrations. This approval marks the fifth indication for PEMFEXY, a ready-to-use liquid formulation designed to simplify treatment by eliminating reconstitution steps. Additionally, effective October 1, 2022, Eagle amended its agreement, reducing future royalties from 25% to 0%-12.5% in exchange for a $15 million one-time payment.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced a settlement with Accord Healthcare regarding patents related to BENDEKA®. Accord can market its product starting January 17, 2028, or sooner under specific conditions. This follows a similar settlement with Hospira. Eagle's CEO expressed satisfaction with the settlement and plans to continue enforcing intellectual property rights related to BENDEKA and its bendamustine franchise.